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Abstract 
Major depressive disorder (MDD) is one of the leading global causes of disability. Symptoms 
of MDD can vary person to person, and current treatments often fail to alleviate the poor 
quality of life that patients experience. One of the two, core diagnostic criteria for MDD is the 
loss of interest in previously pleasurable activities, which suggests a link between the disease 
aetiology and reward processing. Cognitive impairments are also common in patients with 
MDD, and more recently, emotional processing deficits known as affective biases have been 
recognised as a key feature of the disorder. We consider affective biases in the context of 
other reward-related deficits and examine how affective biases associated with learning and 
memory may interact with the wider behavioural symptoms seen in MDD. We discuss recent 
developments in how analogues of affective biases and other aspects of reward processing 
can be assessed in rodents, as well as how these behaviours are influenced in models of MDD. 
We subsequently discuss evidence for the neurobiological mechanisms contributing to one 
or more reward-related deficits in preclinical models of MDD, identified using these 
behavioural assays. We also consider how the relationships between these selective 
behavioural assays and the neurobiological mechanisms for affective bias and reward 
processing could be used to identify potential treatment strategies.  
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1. Introduction 
Depression is currently the leading global cause of disability [1]. According to the DSM-5, 
clinical depression or major depressive disorder (MDD) is a serious mood disorder 




or pleasure in almost all activities, slowness of thought processes/physical movements, and a 
diminished ability to think or concentrate [2]. 
This latter symptom may relate to two types of cognitive dysfunction experienced by patients 
with MDD, affective biases and cognitive deficits [3]. In this review, we focus on affective 
biases, which refer to how emotional or ‘affective’ states alter different cognitive processes. 
These biases can influence multiple cognitive domains including learning, memory and 
decision-making [4]. Affective biases have also been linked to the development of other 
symptoms of the disorder, suggesting some inter-relationship between negative affective 
biases and depressed mood, amotivation, anhedonia etc. [5]. It has been suggested that 
cognitive impairments that do not directly involve emotional/affective stimuli could still be 
linked to affective biases, for example, greater sensitivity to negative feedback from cognitive 
tasks or reduced positive associations during cognitive tasks involving rewards could lead to 
changes in goal-directed behaviour and motivation to perform the task [4]. 
Although descriptive accounts and more formal diagnoses of depression have been made for 
some centuries [6], it is only more recently that the idea of heterogeneity in depressed 
populations has been addressed. An individual patient can have a number of symptoms but 
not share a single one with another patient, even though they are diagnosed with the same 
disorder [7]. Despite this, treatments are not personalised to match the symptoms present in 
each patient, partly because we do not yet have a full understanding of the neurobiology 
underlying symptoms individually. Differences in the neurobiology of components in reward 
processing are becoming increasingly recognised [8], some of which can match to symptoms 
seen in MDD patients, and MDD can be seen as a disorder of reward processing [9]. Thus, in 
order to understand the neurobiological mechanisms of this complex disorder, we need to 
analyse the individual reward-related symptoms of MDD, for which reliable animal models 
and translational behavioural assays are essential.  
Current animal models of depression appear to demonstrate face validity in relation to 
behaviours comparable to distinct symptomology defined by the DSM criteria of MDD, 
including impairments following exposure to chronic stress, a major risk factor for depression 
[10, 11]. Whilst these behavioural assays (discussed in section 3) show good validity in terms 
of stress-induced behavioural deficits and are sensitive to some antidepressant treatments, 
how well they recapitulate the human condition, and hence can demonstrate translational 
validity, has been questioned [12, 13]. Recently, the idea that affective biases can be modelled 
in animals and provide a more translational approach to studying MDD in non-human species 
has emerged. The nature of the animal experiments has meant that such behaviours are often 
seen as biases in processing of reward-related stimuli, which has led us to consider the wider 
deficits in MDD, particularly anhedonia and the loss of motivation for previously rewarding 
activities [9, 14, 15].  
Reliable behavioural assays in animal models can help to parse the underlying neurobiological 
mechanisms of these deficits, as well as how they interact, and provide clear targets for 
treating individual symptoms [8]. Traditional behavioural assays have focused on symptoms 
of behavioural despair/learned helplessness, in which MDD patients are conditioned to 




rodents, this is often measured with the forced swim test (FST) for both mice and rats, or the 
tail suspension test (TST) for mice. Inescapable shock is also described as a method to induce 
learned helplessness [17] and has been used to induce a depression-like phenotype in animals 
with evidence for both vulnerable and resilient populations [18, 19]. In the FST, rodents are 
placed into an open container of water for a short period of time and their behaviour is 
recorded [20]. The animal swims around the container and attempts to escape, but eventually 
they stop moving and stay immobile. The time taken for the animal to become immobile can 
be used to measure this theory of learned helplessness. Pharmacological studies with pro- 
and anti-depressants have helped to validate this assay, with immobility time reducing with 
pro-depressants such as stressors, and increasing with typical antidepressants (see [21, 22] 
for a full review). The TST works on a similar principle, where mice are suspended by their tail 
so cannot escape. Immobility time is again used as a marker of learned helplessness [23].  
Although widely used in both fundamental biology research and drug development, the 
validity of these methods has been questioned, particularly given evidence of a number of 
false positive and false negative findings [23-25], and a lack of sensitivity to atypical 
antidepressants [26]. Impairments in immobility time is observed in some, but not all, disease 
models where risk factors for MDD have been used (for a full review of animal models of 
depression, see [27]). For example, the FST and TST are generally sensitive to stress-related 
manipulations, but deficits are not reliably observed in immunomodulatory or early life 
adversity interventions [28-31]. Recent arguments against the validity of such measurements 
include suggestions of anthropomorphising natural rodent survival and adaptation 
mechanisms [29], as well as the possibility of changes in motor function underlying these 
behaviours [32]. Although these methods are some of the most commonly used to measure 
depressive phenotypes and can, in some cases, be used to screen novel psychotropic drugs, 
they cannot be said to accurately model ‘depressive phenotypes’ that would be seen in 
patients (for detailed reviews see [33, 34]).   
This review will focus on direct assays of reward-related deficits which can be translated to 
symptoms often seen across patients with MDD. As anhedonia, the reduced ability to 
experience pleasure, is a core symptom of MDD, the most commonly used assay of reward-
related deficits in rodents aims to model this symptom in the sucrose preference test (SPT), 
in which overall consumption of a rewarding solution containing sucrose in comparison to 
plain water is measured as a choice test [35]. This method has been used for decades as one 
of the go-to measurement of depressive-like behaviours and reduced sucrose preference has 
commonly been assumed to indicate consummatory anhedonia [11, 36]. However, it is 
important to note, there are many limitations in the current assays of reward deficits in 
animal models. For example, the direct link between sucrose preference and anhedonia has 
been questioned over the years [13, 14, 37-40]. While a reduced hedonic reaction to sucrose 
would be expected to lower sucrose preference, it should also be noted that general 
consumption of reward relies highly on being motivated to attain it, and choice tests require 
intact cognitive processes to learn where the rewarding solution is. Thus, it cannot be 
concluded that differences in overall consumption of sucrose or sucrose preference 
specifically reflect hedonic deficits alone. This highlights the importance of improving current 




are claimed to, and can therefore be used to parse differences in the underlying 
neurobiological mechanisms of this complex psychiatric disorder. 
It can be difficult to reliably separate reward-related deficits given their interactions, and 
measurements of anhedonia in rodent models are often focused on consummatory 
behaviours, which may not capture the possibility that patients also experience anticipatory 
anhedonia [41, 42]. However, recent developments in our work investigating affective biases 
in putative models of depression has revealed some interesting and novel behavioural 
differences which could provide new insights into these questions.  
In this review, we aim to highlight the importance of dissociating symptoms of MDD with 
more sensitive behavioural assays in rodent models, and discuss the findings to date which 
have used these methods. Further, we will summarise these findings to describe the potential 
neurobiological underpinnings of reward processing deficits relevant to symptoms of MDD. 
As affective biases are a key symptom of MDD and novel, translatable methods have recently 
begun to be described, this review will focus on these recent developments, as well as how 
these biases may be dissociable from, but also interact with, other reward-related deficits. 
2. Affective biases in MDD 
Impairments in cognitive processes such as executive function, attention, learning and 
memory and decision-making have been shown to be core features in patients with MDD [43]. 
Such impairments can be separated based on whether they involve dysfunctional processing 
of emotional information (“hot”), for example faces displaying different emotional 
expressions, or dysfunctional processing of information without emotional influences 
(“cold”), for example verbal learning (see Roiser & Sahakian 2013 for a full review [44]). 
Patients with MDD show significant impairments in the processing of both “hot” and “cold” 
stimuli, with some “cold” processing deficits proposed to result from negative emotions 
developed from feedback in the tasks [44]. This concept of “hot” stimuli processing can also 
be applied to reward-related stimuli, given that rewards have emotional value [4].  
Early theories of cognitive dysfunction in MDD note that negative stimuli and events are more 
salient to patients compared to healthy individuals, attributed to a negative self-schema 
caused by past experiences, which can lead to biases in processing their environment [45]. 
These ‘cognitive’ biases can influence learning and memory, for example, patients often 
demonstrate increased recall of negative stimuli compared to positive stimuli [46], and learn 
to assign negative connotations to ambiguous stimuli, whilst healthy individuals would show 
more positive associations [47, 48]. This processing bias induces negative expectations of 
future events, and can alter other cognitive domains  such as decision making and judgement 
[49, 50]. In addition to enhanced negative processing biases, patients with MDD show 
reduced biases toward positively valenced stimuli including reduced recognition or 
interpretation of positive emotions, decreased memory for positively associated words and 
blunted responses to rewards [51, 52]. Studies have also shown that acute antidepressant 
treatment can enhance positive biases in healthy volunteers and patients with MDD [53-55]. 




mood disorders, and the neuropsychological hypothesis of antidepressant action see Harmer, 
Duman and Cowen 2017 [56]. 
A task frequently used to specifically measure reward processing biases in humans is the 
‘Response Bias Probabilistic Reward Task’ [57]. Here, subjects are presented with two 
ambiguous stimuli to which they must discriminatively respond to gain a reward. The correct 
identification of one stimulus is more frequently rewarded, so the expected response of 
healthy subjects would be to develop a bias for responding to the more frequently rewarded 
stimulus, thus demonstrating intact learning and decision-making about reward-related 
stimuli. Patients with MDD consistently show an impaired response bias to the more 
frequently rewarded cue when the reward is not present, compared to healthy controls [58-
61]. This suggests depressed patients have impaired learning and decision-making biases for 
“hot” stimuli, i.e. stimuli with emotional value. 
More recent theories of these deficits have argued that emotional processing biases are not 
solely a result of negative past experiences, but are also driven by aberrant neurobiological 
mechanisms. Such mechanisms are thought to involve environmental and/or genetic factors 
altering the normal transmission of monoamines [4], which have long been hypothesised to 
play a role in depression [62]. This dysfunctional monoamine transmission may then induce 
negatively biased expectations, and so it has been suggested these play a causal role in the 
development and treatment of depressive symptoms [63, 64].  
Evidence for this latter theory comes from studies demonstrating that emotion and reward 
processing biases are present in individuals at risk of depression, but not yet demonstrating 
other symptoms [65-67], as well as patients in remission [68]. Some studies have also shown 
that negative processing biases can predict future diagnoses of MDD [69-71], and can be 
correlated with measures of anhedonia [58], whilst the presence of depression in other 
disorders has been associated with deficits in reward learning biases [72]. Finally, 
monoaminergic antidepressants are shown to reduce negative and induce positive affective 
biases prior to changes in mood [64, 73], suggesting affective states influenced by monoamine 
transmission works in a bottom-up approach to alter processing of rewarding stimuli leading 
to mood changes [74]. 
These findings may indeed suggest a relationship between affective biases and the 
development of other symptoms of depression. However, as mentioned previously, the 
symptomology of MDD is highly heterogeneous, and some evidence suggesting negative 
biases can be ameliorated through specifically treating other symptoms of depression [75]. 
2.1. Relationship between affective biases and other reward-related deficits 
For the purposes of this review, reward-related deficits are categorised in to three 
mechanisms of processing involving hedonic responses (‘liking’), motivation (‘wanting’), and 
learning (including anticipation of reward and decision-making capability) [76]. A lack of 
consistent evidence for the traditional view of consummatory anhedonia in MDD patients has 
led to a re-conceptualization of the term ‘anhedonia’ to refer to an “impaired ability to 
pursue, experience and/or learn about pleasure” [77], suggesting anhedonia is not a deficit 




of heterogeneity in patients indicates anhedonia might seem to include these three aspects, 
but they may not be seen all at the same time, nor all within the same individual.  
Evidence suggests these three aspects are inter-related. As mentioned previously, affective 
biases are argued to precede other symptoms of MDD including anhedonia and motivational 
deficits. In contrast, formal psychological models of learning suggest that reward value 
determines the degree and strength of learning about reward [78]. Thus, an under-valuation 
of reward, perhaps by reduced hedonic experience, could impair learning about affective 
stimuli. Similarly, motivationally-relevant cues for rewards are shown to modulate cognitive 
processes such as attention in healthy mice, but not transgenic schizophrenia models [79]. 
Thus, even though affective bias may influence other symptoms in some cases, the interaction 
between hedonic experience, motivation, and learning may be multifaceted. 
Although there are potential interactions between reward-related deficits, it is unlikely that 
they can be reduced to any single cause or set of causes. Patient symptoms are highly 
heterogeneous; there can be elements of reward processing which are intact whilst other 
aspects are dysfunctional. In animal models, combining behavioural assessments of individual 
aspects has identified dissociations between the presence of anhedonia and negative 
affective bias following pro-depressant treatments [80]. Models of schizophrenia have also 
been shown to display reduced positive bias for a greater reward value [81], whilst other 
studies show they do not show anhedonia-like deficits [82]. In addition, pharmacological 
agents have been identified as specific to influencing either ‘wanting’ or ‘liking’ separately, or 
in opposite directions [83]. This indicates mechanisms underlying hedonic experience, 
motivation and learning can be separated, implying that – while they may interact – reward-
processing deficits are not monolithic, and each needs to be investigated individually.  
3. Reward-related deficits in rodents 
A major aim for developing tests that can dissociate different symptoms of clinical depression 
in animal models is to apply them to understanding the neurobiological mechanisms 
underpinning these symptoms and elucidate the causes behind this disorder. Initial theories 
of the neurobiological underpinnings of MDD suggest symptoms are caused by a deficiency 
in monoamine levels or neurotransmission in the central nervous system, mainly evidenced 
by understanding the mechanisms of antidepressants [84]. However, the low success rate in 
treating MDD has led to developments of more recent theories which encompass a range of 
potential causal mechanisms, such as stress-induced neurotrophic deficits [85, 86] and 
aberrant glutamatergic and GABAergic transmission [87]. There are also several different risk 
factors which contribute to the development of MDD, suggesting a number of possible 
biological and genetic causes of the disorder [14].  
Here, we discuss three major types of reward-related deficit and the behavioural assays used 
to measure these deficits in both patients and rodent models of MDD. We then describe our 
current understanding of the neurobiological substrates that might be underpinning these 
behaviours from using pharmacological and psychological manipulations, with the aim of 
elucidating some distinct, and some interacting, neurobiological mechanisms contributing to 




3.1. ‘Cognitive’ Impairments 
Given that impairments in different cognitive domains are a major component of MDD in 
patients, it is unsurprising that many assays have been developed to capture these 
impairments in rodents. Rodents where a disease model is induced using manipulations based 
on relevant risk factors have been shown to develop impairments in multiple types of learning 
and memory, ranging from working memory to associative learning (see [88]) with examples 
summarised separately below.   
3.1.1. Associative learning 
Pavlovian associations between a neutral stimulus and an unconditioned stimulus (i.e. 
reward) are well known to be formed with repeated pairings [89], and can be strengthened 
with greater reward value or altering expectation of reward through prediction error [78]. 
Instrumental associations are formed between a neutral stimulus requiring a response to 
produce a reward [90]. Dysfunctional associative learning has been linked to the development 
of depression, with patients often demonstrating impairments in positive reward associations 
[91].  
Instrumental learning for reward-related stimuli in rodents typically involve tasks of lever 
pressing or nose poking to trigger the release of a reward. In one study, rats were trained to 
press a lever for delivery of a sucrose solution. Healthy rats produce progressively more lever 
presses as the number of training days increase, indicating they are learning the stimulus-
response association, and rodent models of depression have been shown to display a 
reduced/slower improvement  [92]. 
Many Pavlovian associative learning tasks in rodents involve fear conditioning, for example, 
Darcet et al [93] trained mice to associate being placed in a conditioning chamber once with 
a foot shock. Models of depression such as the chronic corticosterone model display reduced 
freezing time when re-introduced in to the chamber, suggesting reduced fear conditioning 
strength. However, since reward-related deficits are a core component of depression 
symptoms, reward-related associative learning tasks have also been developed.  
In similar, contextual Pavlovian association tasks, Papp et al [11] demonstrated that healthy 
rodents show a greater preference for the environment in which several types of rewards 
were presented to them, indicating a learned conditioned place preference (CPP). However, 
models of chronic unpredictable stress showed reduced CPP, indicating they had reduced 
Pavlovian associative learning of reward-related contextual environments.  
Xu et al [94] trained rats to enter a magazine for a sucrose reward, then paired the presence 
of a blue light with the delivery of this reward (stimulus-outcome association). They found 
that the chronic corticosterone rat model of depression did not demonstrate an increased 
number of magazine entries as would be expected with improved learning compared to 
controls, indicating that some models of depression display impaired reward-related 
associative learning. 




The influence of emotional cues on cognitive function is a major area of depression research 
[95] and the reward neuro-circuitry has been heavily linked to disrupted cognition in MDD 
[96]. Thus, changes in processing of rewarding stimuli is an important aspect to investigate 
when assessing rodent models. 
As mentioned previously, the Response-Bias Probabilistic Reward Task (PRT) is used in patient 
populations to assess biases in reward processing, and as a result of this a translational 
method for rodent models has been developed [97]. Rats were trained to discriminate 
between two auditory stimuli, each of which would require a specific operant response to 
gain a reward. They were then presented with similar tones, and correct discriminative 
responses to one tone would be reinforced with a reward more frequently than correct 
responses to the other tone. Like in patient studies, healthy rats develop response biases 
toward the stimulus more frequently rewarded, indicating a clear positive response bias.  
Alternatively, the probabilistic reversal learning task (PRL) has also been developed, which 
assesses alterations in decision-making to positive and negative feedback, enabling detection 
of changes in reward sensitivity [98]. In this task, rats are trained to nose poke in an 
illuminated hole for a reward, and then presented with two illuminated holes in which one 
was more frequently reinforced. The two holes’ probability of reward was then reversed 
following eight consecutive correct choices in the more frequently rewarded hole. In a 
validation experiment, it was shown that altering serotonin levels differentially influenced the 
ability to shift decision-making following reversal (i.e. cognitive flexibility), win-stay behaviour 
(i.e. reward sensitivity) and lose-shift behaviour (i.e. negative feedback sensitivity). These 
findings are similar to observations in healthy humans [99], and sensitivity to negative 
feedback is enhanced in depressed patients [100]. 
Emotional decision-making biases in humans can be measured by the affective Go/No-Go 
task, where subjects are presented with positive or negative stimuli, e.g. images, to which 
they are required to respond. They are also required to withhold responding to distractor 
stimuli. Depressed patients display attentional biases for negative stimuli in this task [101], 
and also tend to show a bias toward withholding responses with negative outcomes [102]. 
Decision making and interpretation biases induced by affective biases in rodents can be 
measured by the judgement bias task (JBT) [103]. Rodents are trained to produce one 
response to the presentation of a positive stimulus, and a different response to the 
presentation of a negative or less positive stimulus. Rodents hypothesised to have a positive 
affective state display a bias whereby ambiguous stimuli are more likely to elicit the response 
trained to the positive stimulus. In contrast, rodents in a negative affective state exposed to 
the same ambiguous stimuli display a bias to responses trained to the negative stimulus [104-
107]. Thus, their judgements and/or interpretations of stimuli can be altered by changes to 
their affective states. A novel version of this task has also been developed which utilizes 
rodent natural investigative behaviours rather than lever pressing, which recapitulate similar 
effects of affective state manipulations on judgement bias [108]. Further, recent studies have 
evaluated translational human versions of this task, which link negative biases with 




More recently, the affective bias test (ABT) has been developed to address the gap in 
assessing learning and memory impairments driven by affective biases (for full reviews of the 
ABT see [4, 12, 74]). In this task, rodents associate a particular digging substrate with a reward 
and a different substrate with no reward (figure 1a). Rodents hypothesised to have a 
pharmacologically induced positive affective state during the presentation of one reward-
paired substrate will demonstrate a bias toward that substrate in a choice test with a different 
reward-paired substrate in which their affective state was not manipulated (neutral). In 
contrast, rodents in a negative affective state will show bias toward the neutral reward-paired 
substrate. [80, 111]. Thus, biases in reward-related learning and memory can be influenced 
by affective states and such biases can be modelled in rodents.  
This task has also been modified to investigate the effects of long-term affective state 
manipulations, for example chronic drug treatments or environmental stressors on reward 
learning and the ability of an animal to develop a bias towards a cue previously associated 
with a higher value reward. In the modified ABT (mABT, figure 1b), rodents are given pairing 
sessions to learn the association between one digging substrate and a high value reward (i.e. 
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Figure 1. Method overview of the original affective bias test (ABT, a) and the modified ABT (mABT, b).  
In the ABT, rodents undergo four pairing sessions of an affective state-manipulating drug with one type of 
digging substrate (A) or a vehicle with another type (B). A+ and B+ are both rewarded with one reward pellet, 
but are presented alongside a ‘blank’ substrate with no reward (C-). On a preference test day, they are given 
the choice between A or B to investigate with random reinforcement. If their affective state at the time of 
learning about A was positive, they display a preference for A, and vice versa show a bias for B if their 
affective state was negative at the time of learning about A.  
In the mABT, rodents undergo a chronic affective state manipulation via drug treatment or environmental 
factors, then are given four pairing sessions with one digging substrate containing two reward pellets (A++) 
or another substrate containing one reward pellet (B+), each presented alongside C-. Rodents with a neutral 
affective state display a preference for A during the choice test compared to B. If the chronic manipulation 
is proposed to induce a positive affective state, this preference for A will increase, whilst if the manipulation 
is proposed to induce a negative affective state, rodents will show reduced or no preference for A. 
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two reward pellets), and another digging substrate with a low value reward (i.e. one reward 
pellet). A healthy animal develops a bias toward the substrate associated with the higher 
valued reward when presented with a choice between the two previously paired substrates, 
i.e. a reward-induced positive bias. In contrast, rodents in a putative negative affective state 
display no or reduced bias for the higher valued reward [80]. Thus indicating that a negative 
affective state can alter reward-related learning and memory. Important for this discussion, 
these same animals did not show consistent impairments in SPT or PR tasks suggesting this 
reward-learning deficit is not mediated by the same underlying neurobiology as reward 
consumption and motivation, and does not result from a change in either of these aspects of 
reward processing [80]. 
Some theories of associative learning suggest it is an automatic, mechanistic process which 
does not involve higher-order cognition, although it is argued that this is true for smaller 
animals like rodents but human learning involves more complex expectancies of reward [112]. 
The loss of reward-induced positive bias that is observed in the mABT could reflect deficits in 
expectancies and anticipation of reward, given that this task requires animals to use more 
complex cognitive processes involving recalling prior experiences of reward-related stimuli, 
modulate decision making and stimulate a directed behaviour [80].  
3.1.3. Neurobiological substrates of affective bias 
In humans, reductions in monoamines including serotonin, dopamine and noradrenaline have 
been linked to impaired reward learning [113], and negative processing biases of rewarding 
stimuli [114-118], whilst serotonergic receptor antagonists negatively shift affective 
processing biases [119]. In remitted MDD patients, depletions in monoamines can trigger 
symptom relapse and changes in emotional processing [120, 121] without directly influencing 
mood [122], suggesting this generates a potential vulnerability for developing depressive 
symptoms. This is in line with theories of affective bias preceding changes in mood. 
In rodents, pharmacological manipulations have been used to identify potential 
neurochemical factors and neurobiological pathways in affective processing biases (see table 
2 for a list of example evidence, for a detailed review see [74]). Taking the main affective bias 
assays in turn, administration of D2/D3 agonists expected to decrease dopamine signalling 
are shown to impair reward bias in rats using the PRT described in 3.2.2 [97], which matches 
findings in humans using the original task [123]. Psychosocial stress also impairs reward bias 
in both species with the PRT [124, 125]. 
Using the JBT, the number of studies investigating neurobiological mechanisms are still 
limited but do suggest involvement of monoamines (dopamine and 5-HT, although data for 
5-HT is mixed and may depend on acute versus chronic treatment) and the endocannabinoid 
system in inducing positive interpretation biases [126, 127]. The benzodiazepine inverse 
agonist and, interestingly, noradrenaline re-uptake inhibitors induce a negative bias following 
acute treatment [127]. Further, psychosocial stress induces negative interpretation biases 
[107] whilst environmental enrichment enhances positive biases [128]. 
Negative learning and memory biases have been found in the ABT with acute antagonism of 




influence biases [111], indicating the affective state manipulation drives altered learning and 
memory bias, not simply activation of the dopamine reward system. Monoamine depletors, 
such as tetrabenazine, and several immunomodulators are also shown to induce negative 
biases in the ABT [80]. Furthermore, chronic treatment with interferon-alpha (IFN-α) or 
retinoic acid reduced reward-induced positive biases in the mABT compared to vehicle 
treated controls, whereas consummatory behaviour in the SPT was unaffected by these 
treatments [80]. IFN-α is used to treated viral diseases, such as hepatitis C, and has been 
associated with the development of depressive symptoms in patients receiving this treatment 
[129]. Similarly to findings in the ABT, hepatitis C patients receiving this treatment present 
negative biases in processing of emotional facial expressions, though these biases did not 
correlate with depression ratings [130]. 
Taken together, these current findings suggest that affective biases in learning and memory 
are influenced by several biological pathways including altered monoamine transmission, 
immunomodulators and stress. Findings in the ABT and JBT using conventional and rapid-
onset antidepressants (discussed in section 4) suggest that the formation of affective biases 
may be mediated by the amygdala region, while recall of these biases are mediated through 
higher cortical and hippocampal regions [106, 131]. These regions can then input to the limbic 
reward pathway suggested to play a role in other reward-related behaviours [132, 133]. 
Neurobiological studies have linked the amygdala to the formation of an affective bias and 
the medial prefrontal cortex linked to recall of this bias [131]. Comparison with other reward 
behaviour assays, such as the SPT, suggest the neurobiological mechanisms underpinning 
affective biases are, in some cases, separate from other reward-related deficits such as 
consummatory anhedonia. 
3.2. Hedonic experience 
There are three main domains of reward-related impairments observed in MDD patients. 
Deficits in the consummatory hedonic experience derived from rewards, or consummatory 
anhedonia, are most often measured in animal models, in contrast to anticipatory anhedonia. 
3.2.1. Rodent behavioural assays of consummatory anhedonia 
As mentioned previously, the most common method claimed to assess consummatory 
anhedonia-like behaviour in rodents is the sucrose preference test (SPT) [35], however there 
are several limitations with using this test to isolate anhedonia from other reward-related 
deficits, discussed in section 1 of this review.  In patients the ‘sweet taste test’ (STT) has been 
used to assess consummatory anhedonia, whereby they are given varying concentrations of 
sweet solutions and rate their pleasantness/liking on a self-report scale [134]. Although 
anhedonia is repeatedly reported in patients with MDD, self-reported hedonic experience to 
sweet solutions appears unaltered [135, 136], which could suggest measuring consumption 
of sweet solutions is additionally not an accurate measure of anhedonia in patients. However, 
it could also be argued that subjective self-report measurements are not reliable methods to 
assay this symptom of MDD. Further, knowing that patients with MDD are highly 
heterogeneous in which symptoms they present, more sensitive methods that can reliably 




To address some issues with measuring consummatory anhedonia, more selective methods 
have been developed (for more detailed reviews see [13, 137]). One emphasised by Berridge 
and colleagues assesses the natural orofacial reactions to the taste of rewarding or 
unpleasant solutions. Rodents display certain categorical facial expressions when tasting 
pleasant or unpleasant solutions, and the frequency of these reactions can reflect hedonic 
experience and thus are used in studying the neurobiological mechanisms underpinning the 
hedonic processing of reward [138].  
Another selective measure of objective consummatory behaviour can be taken from the 
microstructure of licking. Rodents drink in bouts consisting of multiple licks separated from 
other bouts by longer pauses, and the average number of licks within these bouts (lick cluster 
size, LCS) has a positive monotonic relationship with increasing concentrations of sucrose, 
independent of changes in consumption [139]. This LCS measurement is reduced by 
sensations of pain or nausea [140, 141], and our group have also shown this can be reduced 
in a chronic corticosterone models of depression (Unpublished; [142]), thus suggesting licking 
microstructure can be influenced by negative events and could be used to assay anhedonia-
like phenotypes in rodents. 
Although these methods of assessing consummatory anhedonia in rodents has been refined 
and optimised, and orofacial reactivity has been compared to similar facial expressions 
produced by new born infants, it is still open to question how translatable these are to patient 
symptomology. As discussed previously, there is little evidence showing blunted or altered 
taste reactivity to sweet tastes in depression [135, 143]. Instead, impaired consummatory 
anhedonia has been found following self-reported pleasure ratings [144, 145], alongside 
deficits in anticipatory anhedonia. This apparent difference could reflect a number of factors, 
including difficulties in objectively measuring consummatory behaviour in humans whose 
patterns of eating/drinking are presumably more complex than that of rodents, or that the 
majority of human studies use more monetary rewards than the natural rewards of food and 
water [41]. Nevertheless, reduced LCS and reduced orofacial reactions to sucrose solutions in 
rodents represent a functional analogue of anhedonia (i.e. a reduced response to normatively 
rewarding events), regardless of the subjective experience itself [13]. That said, it is important 
to acknowledge that these simple measures of consummatory behaviour may not reflect the 
complexity of hedonic experience in humans. 
3.2.2. Neurobiological substrates of anhedonia 
Traditional views of the neuropharmacology of anhedonia in MDD suggested that dopamine 
was a core mediator of this reward process, given evidence that dopaminergic receptor 
antagonists appeared to inhibit ICSS and CPP learning [146, 147], as well as reducing sucrose 
preference in the SPT [148]. More recently, the application of more sensitive analyses of 
hedonic experience suggest that consummatory anhedonia is not influenced by dopaminergic 
neurotransmission. Instead, these earlier assessments of ‘anhedonia’ did not appropriately 
dissociate motivational processes from ‘liking’, and dopamine plays a greater role in incentive 
salience than hedonic experience of reward [149-151]. While dopaminergic manipulations 
can influence selective consumption-based assays of hedonic responses - for example, Peciña 




dopamine antagonists – the effects are seen either after multiple sessions or late in extended 
test sessions. This implies the effects of dopamine on hedonic reactions is indirect and may 
rely on interactions with other reward processing aspects, such as learning [13]. 
Furthermore, some studies investigating alteration of serotonergic neurotransmission have 
also found no effect on lick cluster size (LCS), though inhibition does appear to reduce overall 
consumption whilst activation enhances consumption [153, 154]. However, Galistu et al [155] 
demonstrate that the atypical antipsychotic Clozapine does increase LCS without influencing 
overall consumption. Since Clozapine is believed to work through multiple neurotransmitter 
pathways including serotonin and dopamine it could be suggested that some monoaminergic 
transmission is involved in hedonic experience, however, their discussion of findings 
compared to previous research has ruled out the possibility of 5-HT2 receptors and dopamine 
involvement in this process from clozapine’s multiple potential mechanistic actions.  
Opioid receptor stimulation in the nucleus accumbens (NAc) and ventral pallidum (VP) 
increase positive hedonic orofacial reactions to reward [156, 157]. Lick microstructural 
analysis has been less consistent in reporting opioid contribution to hedonic experience, with 
many studies showing direct stimulation with opioid agonists/antagonists does not affect LCS 
[158, 159]. Based on the evidence in orofacial reactivity studies, it is suggested there are 
different ‘hotspots’ in the brains reward system that mediate different aspects of reward 
processing. As such, opioid stimulation in specific regions such as the rostrodorsal NAc shell 
enhance hedonic reactions to reward [160], whilst in different regions opioid stimulation 
enhances motivation/incentive salience [161, 162], which could explain contradictory findings 
with less specific opioid stimulation.  
Benzodiazepines, GABAA receptor agonists, have additionally shown to increase orofacial 
reactions to rewarding solutions, without affecting aversive reactions to a bitter solution 
[163]. Increased LCS following benzodiazepine administration has also been shown using lick 
microstructure analysis [164]. Evidence that blocking opioid receptors can attenuate the 
effects of benzodiazepines on hedonic reactions suggests the mechanisms by which 
benzodiazepines work in hedonic experience may involve opioid neurotransmission [165] 
Recent studies in our group have shown distinct effects on hedonic responses following 
treatment with IFN-α and corticosterone, both known to induce negative affective biases in 
the ABT (Unpublished work; [142]). We found that chronic IFN-α treatment did not affect LCS 
in rats using microstructural analysis of licking, supporting findings from previous SPT data 
[80, 166]. IFN-α also does not alter the rate of sucrose pellet self-administration [167] or brain 
stimulation reward thresholds [168], suggesting its effects on depressive symptoms are not 
related to hedonic experience or sucrose preference.  
We did find that chronic corticosterone treatment significantly reduced LCS in rats, supporting 
previous SPT data [169-171]. Further, psychosocial stress has consistently resulted in reduced 
reward sensitivity as indicated by the SPT [11, 35, 172], but there has been very limited 
investigation of psychosocial stress with more selective measures of hedonic experience 




These findings suggest that consummatory hedonic experience can be influenced by limited 
neurobiological mechanisms, which include stress and opioid transmission, but potentially 
does not directly involve immunomodulatory cytokines or monoaminergic 
neurotransmission. However, many of these studies investigate the pharmacological actions 
on general hedonic experience, but not in the alleviation of impairments, thus it cannot be 
firmly concluded what interaction these neurobiological substrates have on hedonic 
experience without more in-depth investigation. 
3.3. Motivation 
A third major component of reward processing deficits in depressed patients involves 
motivation for reward. For many years motivational processes and hedonic experience have 
been confounded when assessing clinical populations, potentially contributing to the 
difficulty in assessing consummatory anhedonia, as typical self-report measures would not 
adequately separate ‘wanting’ from deficits in ‘liking’ [83]. Motivational processes integrate 
the biological need for a reward, and learning and memory of a reward-associated stimulus 
to drive goal-directed actions to gain the reward [173].  
3.3.1. Rodent behavioural assays of motivational deficits 
One rodent assay that has been used for several decades to investigate the neurobiological 
basis of anhedonia is intracranial self-stimulation (ICSS) [174]. Electrodes are surgically 
implanted in specific regions of the limbic system, such as the ventral tegmental area (VTA), 
such that activation of the area was achieved by the rodent self-stimulating the electrodes 
through responding on a manipulandum. Levels of anhedonia would be scored through 
altering the reward stimulation frequency and assessing how much rodents would respond 
to higher or lower frequencies. Models of anhedonia were suggested to show reduced 
responding to lower frequencies compared to healthy rodents, and the major neurobiological 
pathway thought to be involved in mediating ICSS were dopaminergic [175-177]. However, 
this task is now more associated with motivational processing, rather than hedonic 
experience [14, 178, 179], through measuring willingness to work for a reward. It could also 
be argued that changes in responding to reward frequencies may reflect alterations in motor 
activity, especially given dopamine’s role in motor function [180], however, the discrete-trial 
current threshold version of the ICSS task has been developed to reduce the sensitivity of this 
task to motor impairments [176, 181]. 
Another commonly used method for examining motivation for reward in rodents is the 
progressive ratio (PR) task, in which the number of lever presses required to obtain a fixed 
reward progressively increases, and motivation is assessed as their ‘breakpoint’, i.e. at what 
level of effort required will they stop responding [182]. Humans with motivational deficits 
show dysfunctional dopaminergic transmission [183, 184] and similarly, disrupted 
dopaminergic systems in rodent models impairs motivation in the progressive ratio task [182, 
185, 186] suggesting translational neurobiological mechanisms underpinning behaviours in 
the PR task. However, in animal models of depression or schizophrenia there has been a lack 
of consistent deficits observed in PR tasks [187-189]. There are several limitations of using PR 




motivational or motor impairments, whilst some might also argue PR tasks could be 
influenced by habitual responding or impulse control deficits [185]. See Salamone [184, 191] 
for detailed discussions of a behavioural economics approach suggested to overcome some 
of these limitations with PR tasks, which is beyond the scope of this review. 
Reward motivation deficits are common in patients with MDD [178, 192] and translational 
behavioural assays for these impairments have been developed for humans and animal 
models. In patients, methods such as the computer game-based ‘Effort Expenditure for 
Rewards Task’ (EEfRT) [193] have been employed to measure such motivational impairments. 
Here, subjects have a choice between participating in a low difficulty task (requiring 30 button 
presses in 7 seconds) for a smaller monetary reward or a higher difficulty task (requiring 100 
button presses in 21 seconds) for a greater monetary reward, thus subjects are required to 
use a greater amount of effort to gain a higher value reward. Some studies using this task 
have shown a decreased amount of effort expenditure to gain the higher valued reward in 
both healthy people with higher ratings of anhedonia [42, 193] and with clinical MDD [194, 
195], and some evidence suggests these impairments in the EEfRT are predicted by greater 
levels of anticipatory anhedonia [42, 196].  
The effort-related choice paradigm task is directly comparable to the EEfRT, in which rodents 
are given a choice between pressing a lever several times (most commonly a fixed ratio 5 
schedule) to gain one high value reward, or easily accessing low value lab chow from a bowl 
in the operant chamber [197]. Thus, like the EEfRT, they are required to produce a greater 
amount of effort to gain a higher value reward, and effort-related choice tasks can assess 
alterations in motivation for reward as well as decision-making behaviours.   
3.3.2. Neurobiological substrates of motivational deficits 
As mentioned previously, motivation and effort have become increasingly recognised as a 
process requiring an intact dopaminergic system (see [198-200] for detailed reviews). 
Dopamine antagonists and agonists are widely reported to reduce or increase instrumental 
responding for rewards respectively [197, 198, 201]. Studies have also shown that levels of 
dopamine neurons in the ventrolateral striatum following neurotoxic ablation with 6-
hydroxydopamine positively correlated with number of lever press responses in an operant 
task [201], indicating dopamine transmission in the reward pathway plays a role in mediating 
incentive instrumental responding. Though, there is some contrasting evidence suggesting a 
lack of instrumental response changes following acute dopamine antagonist treatment, but 
rather dopaminergic signalling influenced Pavlovian reward learning [202]. 
The progressive ratio task can be interpreted as measuring the amount of effort rodents are 
willing to put in to gain a reward, indicating their level of incentive motivation for such 
rewards. This task has thus been used to further indicate involvement of dopamine in 
maintaining a high effort for gaining reward [186], as well as opioids [203]. Both dopamine 
and opioid treatment have additionally shown to increase incentive salience for Pavlovian 
associated reward cues, indicating they are involved in multiple types of associative 




More in-depth investigations of dopamine’s role in motivational processing demonstrate that 
manipulators do not affect general food consumption, and in the effort-related choice task, 
antagonist-treated rodents will demonstrate greater preference for freely available chow 
than the reward requiring operant response [182, 197]. This suggests dopamine mainly 
interacts with the instrumental response requirement, that is, initiating and maintaining 
effort for retrieving reward, rather than appetite [204]. Studies in psychiatric patients for 
whom amotivation is a common symptom support these findings using an effort-based 
reinforcement task, demonstrating a correlation between behaviour in this task and striato-
orbitofrontal connectivity which is predominantly a dopaminergic pathway [205].  
Similar findings to dopamine antagonism in the effort-related choice paradigm have been 
shown with agonists of adenosine A2A receptors in the NAc [206, 207], which are believed to 
interact with dopamine and dopaminergic receptors in the neostriatal region. Muscarinic 
acetylcholine receptor agonists too suppress effortful behaviour for reward and enhance easy 
access chow consumption when administered to the NAc core only [208]. Injections of GABAA 
receptor agonists in the VP reproduce this low-effort effect in an FR5 vs chow protocol [209], 
yet when injected to the NAc shell these agonists have no effect on progressive ratio 
behaviour [203].  
Alternately, serotonergic pathways do not appear to play a role in effort-choice/motivational 
processes. Denk et al demonstrated that treatment with a tryptophan hydroxylase inhibitor 
did not affect performance of rats in a T-maze task given a choice between climbing a barrier 
to gain a high valued reward or entering an obstacle-free arm to gain a low reward, whereas 
those treated with a dopamine receptor antagonist showed reduced effort [210]. Similarly, 
Izquierdo et al reproduced this lack of effect of the tryptophan hydroxylase inhibitor on the 
same task, but found that instead rats showed an impaired reversal learning, suggesting the 
serotonergic system may be more involved in cognitive reward processing [211]. However, it 
has been shown that an antagonist for serotonin 2C receptors can enhance instrumental 
responding in a progressive ratio task and increase effort for greater reward in the effort-
related choice paradigm [212]. Given that antagonism of these receptors increase 
dopaminergic firing from the ventral tegmental area and NAc, it is thought that this underlying 
mechanism involves dopamine signalling more than serotonin itself. 
These recent developments in uncovering the psychopharmacology of effort-related choice 
behaviour highlight a specific network of neurotransmitters that interact and target NAc and 
VP regions to regulate motivational processing of reward.  
3.4. Summary 
The challenge of reliably measuring and dissociating reward processing deficits has been 
highlighted through inconsistencies in reporting and treating patient symptoms. Assays often 
used in patients do not effectively differentiate between multiple reward-related 
components that may be disrupted, and as a result, treatments have had poor efficacy. 
Developments in rodent assays of reward-related deficits are beginning to reveal dissociable 
behaviours specifically linked to separate domains of reward processing. Important to this 
discussion is data for the same manipulations inducing dissociable effects on different 




pharmacological treatments were shown to induce a deficit in reward-induced positive biases 
with no effect in the SPT. We have also undertaken a pilot study to investigate reward learning 
using a lever press task where chronic IFN-α treatment had no effect, further supporting our 
conclusions that the effects seen in the modified ABT are specific.  
Findings in these more sensitive pre-clinical behavioural assays have revealed complex 
neurobiological pathways that may be involved in reward processing and their associated 
deficits in disease. Although hedonic value, motivation and reward-related cognition all 
contribute the arising behaviour, animal studies are revealing that important differences 
underlie these behaviours. From recent studies, monoaminergic and GABAergic 
neurotransmitter pathways have been identified as playing a role in mediating affective 
biases and motivational processing, while consummatory hedonic experience appears to be 
mediated more by opioid transmission with some overlapping GABAergic effects. Notably, 
several forms of stress induction negatively influence all three aspects of reward processing, 
whilst immunomodulatory manipulations do not influence current measures of 
consummatory anhedonia, but do modify affective biases. Neuro-circuit analyses are also 
starting to reveal the distinct neural circuits underlying these behaviours [131].  
From the evidence to date, we can support the hypothesis that distinct neurobiological 
mechanisms may underpin reward-related learning and memory deficits in models of MDD, 
as well as mechanisms involved in incentive motivation arising from the re-activation of 
reward-associated memories, compared to hedonic experience [74]. However, there are still 
some overlaps and interactions between these processes which indicate they are not entirely 
separate, thus, heterogeneity seen in patients may arise from differences in aberrant 
neurobiological changes, along with different environmental and genetic factors. Further, 
issues with clinical assessments remain, in particular relating to hedonic experience. 
Development of human tasks that can similarly dissociate between these different aspects of 
reward processing would be valuable both in terms of understanding the relationship 
between these deficits and disease symptoms, but also to enhance the translational validity 
































Figure 2. Specific affective bias deficits with chronic interferon-alpha (IFN-α) treatment.  
Chronic interferon-alpha (IFN-α) treatment induces a deficit in reward-induced positive bias (panel 
A) but has no effect on sucrose preference (panel B).  The data shown in panel A and B are from 
the same animals which received a 14-day treatment with IFN-α (100u/kg, i.p. once daily) or control 
and then tested in the modified affective bias test and a 1% sucrose preference test (data taken 
from Stuart et al., 2017).  In a separate cohort of rats (n=6 per group) a preliminary study using a 
lever press task failed to show any deficit in learning to associated one lever with a higher value 
reward (panel C, data unpublished, Benn et al). In this pilot studies, animals were first trained using 
a continuous reinforcement schedule where each lever was presented on alternate days until they 
were consistently responding with >50 lever presses/session.  Animals were then switched to a 
protocol where both levers were presented and responses paired with either a one or 2 pellet 
reward (left or right lever press was paired with the higher value reward, counter-balanced across 
animals). IFN-α treatment (14 days, once daily, dosing before testing) failed to induce any learning 
deficit with the animals treated with IFN-α showing a higher rate of acquisition (main effect of 
Session F (2.4, 24.1) = 19.95, p <0.001 and Group F (1, 10) = 8.32, p = 0.016 but no Grp*Session F 
(2.4, 24.1) = 0.56, p = 0.607).  Although only a small scale pilot experiment, these data do support 
our hypothesis that the deficits seen in the m-ABT are related to the ability to use reward 
information to guide behaviour when the current information available is ambiguous.  During the 
choice test, rats must rely on their prior knowledge to make a decision about which substrate to 
choose as the reinforcement schedule is randomised for this phase of the task.  In the sucrose 
preference test and lever press task, the information about reward value is available throughout 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4. Antidepressant actions and implications for treatments 
Current treatments for MDD are limited in their robustness, with one third of patients 
remaining unresponsive following several courses of antidepressant and psychological 
therapies [217], and current antidepressants have limited impact on reward processing 
deficits such as anhedonia [218]. To improve treatment efficacy, valid animal models 
appropriately reflecting the behavioural and neurobiological impairments seen in patients are 
essential for testing novel therapies. Here, we will discuss some of the current literature 
describing potential mechanisms of action of antidepressants, as shown in the more sensitive 
behavioural assays discussed previously, and related to our updated knowledge of the 
neurobiological substrates underpinning such behaviours. 
Aberrant monoamine neurotransmission has been implicated in the development of affective 
biases. Typical antidepressants tend to target these systems and have been shown to reverse 
negative affective processing biases and enhance positive biases in patients [219], as well as 
healthy subjects [55]. Similarly, this has been shown with various atypical antidepressants 
that involve some manipulation of monoaminergic pathways [53]. Some of the most 
commonly prescribed antidepressants are selective serotonin reuptake inhibitors (SSRIs), 
which have been shown to increase reward learning in patients [54]. The effects of 
monoamine-targeting antidepressants on other aspects of reward processing deficits is much 
less consistent, often having little effect on motivational deficits and anhedonia in MDD 
patients [15, 220]. Though, patient studies on antidepressant actions in motivation tasks such 
as the EEfRT, along with translational assays of anhedonia, are limited, but recent theories 
suggest dopamine-targeting antidepressants should be used in combination with SSRIs to 
enhance the motivational deficits of depression [221].  
In animal models, studies have shown that reward preference deficits following chronic stress 
seen in the SPT can be reversed with typical antidepressant treatments [35, 222, 223], while 
there is limited pharmacological evidence for antidepressant effects in the more sensitive 
methods of anhedonia discussed previously. Dopamine enhancing drugs not typically 
prescribed as antidepressants have shown to reverse amotivational shifts in the effort-related 
choice task in rats [224], whilst serotonin-targeting typical antidepressants do not [225], 
supporting the specific role of dopamine in motivational processing. However, studies where 
tetrabenazine is used to induce a deficit have shown subsequent reversal with 
monoaminergic antidepressants [225]. 
However, serotonergic modifying antidepressants are shown to enhance positive reward 
sensitivity and learning in the PRL task [98]. Various monoaminergic and atypical 
antidepressants also enhance positive affective biases in the ABT [80, 111, 226, 227] (see 
figure 1 and [74] for a recent overview of antidepressant actions). The recent development of 
these tasks mean no studies, to our knowledge, have yet investigated the effects of these 
antidepressants on reversing negative depression-like phenotypes induced by known risk 
factors.  Thus, more studies are needed to determine whether, and how, these 
antidepressants can alleviate negative processing biases induced by negative affective states, 





Despite this evidence that enhancing monoaminergic transmission may improve affective bias 
and dopamine replenishment could improve motivational deficits, the therapeutic effects of 
monoaminergic antidepressants take several weeks to become effective, even though 
increases in monoamine release can be detected immediately [228]. This observation has led 
to potential implications of more prolonged downstream changes in neuroplasticity leading 
from these monoamine changes in the efficacy of antidepressants [229].  
This theory of the delayed onset action of typical antidepressants has brought about an 
abundance of literature in support of neuro-adaptive changes involvement in the 
development and treatment of MDD symptoms [230-233]. However, a more recent theory 
has been proposed, describing a cognitive neuropsychological mechanism of action for 
antidepressants that combines the clinical and preclinical evidence of affective biases in MDD 
with this neuroplasticity hypothesis [64]. In this model, antidepressants rapidly induce a 
positive shift in the negative processing biases experienced by patients, which is then 
gradually expected to improve the impairments in behaviour and mood. Thus, suggesting 
positive affective biases may not directly enhance mood and other deficits in MDD but could 
provide a cognitive neuropsychological mechanism for this to occur. It also suggests that the 
delayed improvement in mood may result from the need for re-learning positive associations 
between affective and social stimuli [56]. This would also fit with the evidential link between 
neuroplasticity and learning [234], indicating potentially antidepressants improve plasticity 
which improves positive affective learning, or it may be that the improved learning through 
positive affective biases enhances plasticity as suggested in an alternative hypothesis outlined 
by Robinson 2018 [74]. 
Some antidepressants, such as the NMDA receptor antagonist ketamine, are shown to have 
rapid-onset improvements in MDD patients [235], including in patients shown to be 
unresponsive to several courses of typical antidepressant treatments. This is thought to occur 
through a more rapid activation of neuroplasticity changes [236, 237]. However, a new 
proposal suggests differences in delayed vs rapid onset antidepressants might lie in the way 
they influence affective biases [74]. In the ABT, FG7142- and psychosocial stress-induced 
negative affective biases in rodent models can be reduced following ketamine treatment, but 
not treatment with the delayed onset antidepressant, venlafaxine, whereas ketamine failed 
to induce any bias alone [131]. This effect of ketamine was specific to the medial prefrontal 
cortex (mPFC), whilst venlafaxine was specific to the amygdala. These findings could suggest 
that rapid onset antidepressants act upon previously learned negative biases through changes 
in the mPFC to stabilise these biases rapidly, which is separate from delayed onset actions of 
initiating new learning of positive biases in other limbic areas [74]. 
Recent studies using the JBT have also investigated the effects of ketamine on decision-
making biases, demonstrating similar temporal differences between rapid-onset and 
conventional antidepressants in inducing positive biases as seen in clinical populations, as 
well as indicating the involvement of distinct neurobiological substrates underlying these 
differences (for a more detailed discussion see Hales et al [106]). However, there are still 
patients for which these antidepressants do not work at all and are possibly resistant to the 




patients is that these patients may have poorer social support and continuous negative 
environmental interactions that dampen the improvements in affective biases through 
pharmacological treatment alone [56]. This could lead to failure to re-engage with social 
and/or rewarding activities that is essential for re-learning positive experiences.  
Thus, the cognitive neuropsychological model for MDD suggests taking more integrated 
approaches in investigating the underlying causes, as well as treatment, of MDD, and 
potential differences in the neurobiological and behavioural mechanisms of distinct 
symptoms suggest that understanding this complex disorder should involve combining 
assessments of different aspects that are impaired. 
5. Conclusion 
Although hedonic value, motivation and reward-related cognition all contribute to reward 
processing and associated reward-related deficits, important differences underlie these 
behaviours. Biases in the processing of reward-related information, including biases in 
learning and memory and decision-making, have been observed in humans and, more 
recently, in rodents. These behaviours are not directly related to the more typical measures 
of reward, and add another dimension to the discussions relating to how reward-related 
behaviours may be altered in diseases such as MDD. In this review, we show that commonly 
impaired aspects of reward processing could have some distinct neurobiological 
underpinnings. We emphasise the importance of investigating different reward-related 
deficits separately, and potentially combining various sensitive behavioural methods in 
clinical and preclinical research, to thoroughly identify neurobiological targets of individual 
symptoms of MDD, in order to improve the development and evaluation of novel therapies.  
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